BidaskClub cut shares of Forward Pharma A/S (NASDAQ:FWP) from a strong-buy rating to a buy rating in a research note released on Saturday morning.
Several other analysts also recently commented on the company. ValuEngine downgraded Forward Pharma A/S from a hold rating to a sell rating in a research note on Tuesday, September 12th. Jefferies Group LLC restated a hold rating and issued a $6.00 target price (up from $5.00) on shares of Forward Pharma A/S in a research note on Wednesday, September 27th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $17.00.
Shares of Forward Pharma A/S (FWP) opened at 6.05 on Friday. The company has a market capitalization of $285.56 million, a price-to-earnings ratio of 0.31 and a beta of 1.65. Forward Pharma A/S has a one year low of $5.20 and a one year high of $33.00. The stock has a 50 day moving average price of $9.31 and a 200-day moving average price of $18.22.
TRADEMARK VIOLATION WARNING: “BidaskClub Downgrades Forward Pharma A/S (FWP) to Buy” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/2981882/bidaskclub-downgrades-forward-pharma-as-fwp-to-buy.html.
Several institutional investors and hedge funds have recently modified their holdings of FWP. MARSHALL WACE ASIA Ltd acquired a new stake in shares of Forward Pharma A/S in the 1st quarter valued at about $612,000. Marshall Wace North America L.P. acquired a new stake in shares of Forward Pharma A/S in the 1st quarter valued at about $612,000. Citadel Advisors LLC acquired a new stake in shares of Forward Pharma A/S in the 1st quarter valued at about $269,000. Point72 Asset Management L.P. acquired a new stake in shares of Forward Pharma A/S in the 1st quarter valued at about $2,465,000. Finally, Eqis Capital Management Inc. grew its stake in shares of Forward Pharma A/S by 25.5% in the 2nd quarter. Eqis Capital Management Inc. now owns 20,178 shares of the biotechnology company’s stock valued at $410,000 after buying an additional 4,097 shares during the period. Institutional investors own 21.89% of the company’s stock.
Forward Pharma A/S Company Profile
Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.